Market Overview

The U.S. Epigenetics Market Size was valued at USD 592 Million in 2024 and is forecasted to grow to USD 2,845 Million by 2033, reflecting a CAGR of 19.1% for the period 2025-2033. This growth is driven by increasing chronic disease incidences, innovations in precision medicine, and enhanced biomedical research funding boosting epigenetic tool development in oncology and non-oncology applications.

Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

U.S. Epigenetics Market Key Takeaways

  • Current Market Size (2024): USD 592 Million
  • CAGR (2025-2033): 19.1%
  • Forecast Period: 2025-2033
  • Increasing prevalence of chronic diseases like cancer is driving demand for epigenetic diagnostics and targeted therapies.
  • Rapid uptake of personalized medicine using epigenetic analysis is expanding market opportunities.
  • Expanding applications in non-oncology fields such as autoimmune, neurological, and metabolic disorders.
  • Technological advances in next-generation sequencing and bioinformatics enhance epigenetic study efficiency.
  • Collaborations among research institutions, pharma companies, and biotech firms accelerate product development.

Sample Request Link: https://www.imarcgroup.com/united-states-epigenetics-market/requestsample

Market Growth Factors

The U.S. epigenetics market is significantly propelled by increasing innovation in genomic technologies coupled with rising investments in biomedical research. The growing incidences of chronic diseases, particularly cancer, have heightened the need for epigenetic-based diagnostics and therapies. According to a January 2024 research article, the U.S. is expected to have 140 new cancer cases alongside 611,720 cancer deaths in the year, which underscores the urgent demand fueling market expansion. Government initiatives and funding further enhance research capabilities to develop cutting-edge epigenetic tools and therapeutics.

Another driver is the rapid emergence of personalized medicine. Epigenetic tools are increasingly leveraged to identify biomarkers and develop targeted therapies, especially in oncology. The announcement in February 2024 of over 275 million previously unreported genetic variants from NIH's "All of Us Research Program" participants illustrates the expanding capability to customize treatment through epigenetic insights. Pharmaceutical and research collaborations foster the integration of epigenetics into mainstream healthcare, broadening its adoption and market potential.

Technological advancements constitute a major growth pillar, with breakthroughs in epigenome editing tools and next-generation sequencing (NGS) technologies like dCas9 systems improving precision and scalability of epigenetic research. The deployment of AI-driven analysis methods, such as Johns Hopkins Medicine’s DELFI-Pro technology introduced in September 2024, enhances cancer screening accuracy. These innovations facilitate discovery of novel biomarkers and accelerate drug development, reinforcing technology as a fundamental market growth engine.

Market Segmentation

By Product:

  • Reagents: Essential for DNA methylation, histone modification, and chromatin accessibility assays; widely applied in research, diagnostics, and pharmaceutical sectors.
  • Kits: Include Chip Sequencing Kit, Whole Genomic Amplification Kit, Bisulfite Conversion Kit, RNA Sequencing Kit, and others; streamline workflows and ensure experimental reliability.
  • Instruments: Comprise microarray scanners, sequencing platforms, and real-time PCR systems; vital for high-throughput epigenetic modification analysis.
  • Enzymes: Methyltransferases, acetyltransferases, DNases facilitating DNA methylation, histone acetylation, and chromatin remodeling; critical for regulatory pathway studies.
  • Services: Encompass histone modification profiling, DNA methylation analysis, chromatin accessibility studies; provide premium results and support research core focus.

By Technology:

  • DNA Methylation: A major segment due to its role in gene regulation and disease progression; widely used in cancer research and drug development.
  • Histone Methylation: Important for chromatin remodeling and gene expression regulation; relevant to oncology and neurodegenerative diseases.
  • Histone Acetylation: Crucial in transcriptional activation and chromatin accessibility; used in drug discovery and disease modeling.
  • Large Non-Coding RNA: Regulates gene expression and chromatin architecture; promising for diagnostics and therapeutics.
  • MicroRNA Modification: Involved in post-transcriptional regulation; important biomarkers and therapeutic targets.
  • Chromatin Structures: Provide insights into gene accessibility; essential for understanding chromatin dynamics in diseases.

By Application:

  • Oncology: Includes solid tumors and liquid tumors; epigenetic technologies aid understanding tumor progression and targeted therapies.
  • Non-Oncology: Encompasses inflammatory, metabolic, infectious, and cardiovascular diseases; supports novel therapeutic development.

Regional Insights

The Northeast region dominates the U.S. epigenetics market, driven by its concentration of premier universities, research institutions, and biotechnology companies that foster advancements in cancer research and personalized medicine. Collaborative efforts with pharmaceutical companies accelerate epigenetic technology adoption, establishing the Northeast as a leader in healthcare innovations.

Ask an Analyst: https://www.imarcgroup.com/request?type=report&id=20468&flag=C

Recent Developments & News

In June 2024, Bio-rad launched the ddSEQ™ Single-Cell 3' RNA Sequencing Kit and Omnition v1.1 analysis software for single-cell transcriptomics, advancing gene expression studies across multiple fields. In the same month, FOXO Technologies acquired Rennova Health's U.S. healthcare operations, aiming to integrate epigenetic technology into community health and addiction recovery. In November 2024, Quantum-Si Incorporated announced a strategic partnership with Avantor to commercialize proteomics and genetic sequencing solutions in the U.S., enhancing product reach.

Key Players

  • Quantum-Si Incorporated
  • Avantor
  • Bio-rad
  • FOXO Technologies

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302